drugset / Trial / NCT00442832
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Timeline
- Start
- 2006-12
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEFILAVANCIN | Unknown | 2 mg/kg | Intravenous |
| Comparator | Vancomycin | Other / unclassified | 1 g | Intravenous |